Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
P/E ratio for Armata Pharmaceuticals, Inc. (ARMP)
P/E ratio as of 2023: -1.69
According to Armata Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.69. At the end of 2022 the company had a P/E ratio of -1.15.
P/E ratio history for Armata Pharmaceuticals, Inc. from 1993 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.69 |
| 2022 | -1.15 |
| 2021 | -5.69 |
| 2020 | -2.15 |
| 2019 | -1.34 |
| 2018 | -0.32 |
| 2017 | -0.50 |
| 2016 | -0.23 |
| 2015 | -41.74 |
| 2014 | 1.66 |
| 2013 | -0.87 |
| 2012 | -7.57 |
| 2009 | 0.72 |
| 2008 | -0.21 |
| 2007 | -1.58 |
| 2006 | -1.55 |
| 2005 | -2.19 |
| 2004 | -8.64 |
| 2003 | -118.82 |
| 2002 | -10.78 |
| 2001 | -61.34 |
| 2000 | -74.16 |
| 1999 | -66.42 |
| 1998 | -56.25 |
| 1997 | -52.27 |
| 1996 | -39.75 |
| 1995 | -91.21 |
| 1994 | -52.50 |
| 1993 | -2449.42 |